within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB07_Dacomitinib;

model Dacomitinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 2.0027777777777777e-05,
    adminDuration = 600,
    adminMass = 45 / 1000000,
    adminCount = 1,
    Vd = 1.88,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008566666666666667,
    Tlag = 14.1,
    Vdp = 5.39,
    k12 = 0.0006555555555555555,
    k21 = 0.0006555555555555555);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dacomitinib</td></tr><tr><td>ATC code:</td><td>L01EB07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>45</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1880</td><td>L</td></tr>
    <tr><td>clearance:</td><td>72.1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dacomitinib is an oral, irreversible second-generation tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR). It is used for the treatment of non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Dacomitinib is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on adult patients with advanced solid tumors including NSCLC in multiple phase I trials.</p><h4>References</h4><ol><li><p>Piscitelli, J, et al., &amp; Tan, W (2022). The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib. <i>Clinical drug investigation</i> 42(3) 221–235. DOI:<a href=\"https://doi.org/10.1007/s40261-022-01125-x\">10.1007/s40261-022-01125-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35195881/\">https://pubmed.ncbi.nlm.nih.gov/35195881</a></p></li><li><p>Takahashi, T, et al., &amp; Yamamoto, N (2012). Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. <i>Investigational new drugs</i> 30(6) 2352–2363. DOI:<a href=\"https://doi.org/10.1007/s10637-011-9789-z\">10.1007/s10637-011-9789-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22249430/\">https://pubmed.ncbi.nlm.nih.gov/22249430</a></p></li><li><p>Chen, X, et al., &amp; Hu, P (2018). Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 48(5) 459–466. DOI:<a href=\"https://doi.org/10.1080/00498254.2017.1342881\">10.1080/00498254.2017.1342881</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28648122/\">https://pubmed.ncbi.nlm.nih.gov/28648122</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EB07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dacomitinib;
